Skip to main content

Table 2 Prevalence of Pfdhfr and Pfdhps mutations according to IPTp-SP groups

From: Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso

Mutation allele Total (N = 101) IPTp-SP− (n = 52) IPTp-SP+ (n = 49) Crude OR 95% CI P value
Pfdhfr N51I      0.003
 No 29 (28.7) 8 (15.4) 21 (42.9) 1  
 Yes 72 (71.3) 44 (84.6) 28 (57.1) 0.24 (0.09–0.62)  
Pfdhfr C59R      
 No 58 (57.4) 37 (71.2) 21 (42.9) 1 0.005
 Yes 43 (42.6) 15 (28.9) 28 (57.1) 3.29 (1.44–7.50)  
Pfdhfr S108N      
 No 36 (35.6) 22 (42.3) 14 (28.6) 1 0.1
 Yes 65 (64.4) 30 (57.7) 35 (71.4) 1.83 (0.80–4.20)  
Pfdhps A437G      
 No 20 (19.8) 11 (21.2) 9 (18.4) 1 0.7
 Yes 81 (80.2) 41 (78.8) 40 (81.6) 1.19 (0.45–3.19)  
Pfdhfr double mutation      0.7
 No 60 (59.4) 30 (57.7) 30 (61.2) 1  
 Yes 41 (40.6) 22 (42.3) 19 (38.8) 0.86 (0.40–1.91)  
Pfdhfr triple mutation      0.1
 No 75 (74.3) 42 (80.8) 33 (67.4) 1  
 Yes 26 (25.7) 10 (19.2) 16 (32.6) 2.04 (0.82–5.07)  
≥2 Pfdhfr mutation      0.3
 No 34 (33.7) 20 (38.5) 14 (28.6) 1  
 Yes 67 (66.3) 32 (61.5) 35 (71.4) 1.56 (0.69–3.60)